InterCure Ltd
TASE:INCR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
444
1 254
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InterCure Ltd
Long-Term Debt
InterCure Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
I
|
InterCure Ltd
TASE:INCR
|
Long-Term Debt
â‚Ş102.8m
|
CAGR 3-Years
192%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Long-Term Debt
$16.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
7%
|
||
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Mediwound Ltd
NASDAQ:MDWD
|
Long-Term Debt
$6.4m
|
CAGR 3-Years
58%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Long-Term Debt
â‚Ş13.9m
|
CAGR 3-Years
92%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Long-Term Debt
â‚Ş101.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
What is InterCure Ltd's Long-Term Debt?
Long-Term Debt
102.8m
ILS
Based on the financial report for Dec 31, 2023, InterCure Ltd's Long-Term Debt amounts to 102.8m ILS.
What is InterCure Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
192%
Over the last year, the Long-Term Debt growth was -16%. The average annual Long-Term Debt growth rates for InterCure Ltd have been 192% over the past three years .